<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/872D8701-44D2-4D3C-B113-A795FA40D61F"><gtr:id>872D8701-44D2-4D3C-B113-A795FA40D61F</gtr:id><gtr:name>University of Helsinki</gtr:name><gtr:address><gtr:line1>Siltavuorenpenger 20 C</gtr:line1><gtr:line4>Helsinki</gtr:line4><gtr:line5>FI-00170</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>Astbury Centre</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/872D8701-44D2-4D3C-B113-A795FA40D61F"><gtr:id>872D8701-44D2-4D3C-B113-A795FA40D61F</gtr:id><gtr:name>University of Helsinki</gtr:name><gtr:address><gtr:line1>Siltavuorenpenger 20 C</gtr:line1><gtr:line4>Helsinki</gtr:line4><gtr:line5>FI-00170</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/26630796-84D4-4FD5-AABD-B7B5C3A10166"><gtr:id>26630796-84D4-4FD5-AABD-B7B5C3A10166</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:surname>Goldman</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/922C0AB1-2760-4271-9050-1202D7C30709"><gtr:id>922C0AB1-2760-4271-9050-1202D7C30709</gtr:id><gtr:firstName>Roman</gtr:firstName><gtr:surname>Tuma</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E141AE7D-4DD0-4962-BB02-DFF6A53ADD3D"><gtr:id>E141AE7D-4DD0-4962-BB02-DFF6A53ADD3D</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:surname>Harris</gtr:surname><gtr:orcidId>0000-0002-2812-1651</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FM021610%2F1"><gtr:id>A3580E9D-8D2D-41E1-B65D-8E88451D64C6</gtr:id><gtr:title>Exploiting the structure of integral membrane pyrophosphatases</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/M021610/1</gtr:grantReference><gtr:abstractText>Even though they are targets for 60% of current drugs, integral membrane proteins account for less than 2% of the structures in the protein databank. Furthermore, fast kinetic studies on them have been mostly restricted to those with chromophores, like cytochrome c oxidase. This work will build on our ground-breaking x-ray structure of Thermotoga maritima Na+-pumping pyrophosphatase (TmPPase), published in 2012. Integral membrane pyrophosphatases (mPPases) are evolutionarily conserved novel &amp;quot;primary&amp;quot; ion pumps, interconverting the free energy in the phosphoanhydride bond of pyrophosphate into a sodium and/or proton motive force. They are completely unrelated to the rotary ATPases. They occur in plants, protozoan parasites and in (archae)bacteria but not in multicellular animals, and they appear to be essential under conditions of low-energy stress: knockout mutations render protozoan parasites non-infectious, for instance. Their coupling mechanism is essentially unknown. Our vision is to use structural, single molecule and functional studies to identify the precise mechanism of action in mPPase as the necessary first step for developing hit molecules. This work will have important long-term benefits for animal health, food security, and human disease.

mPPases occur in protozoan parasites like Trypanosoma spp (Nagana, sleeping sickness), Toxoplasma gondii (infecting up to 90% of pigs), not to mention Plasmodium falciparum (malaria). These diseases have a huge impact on both food security and human health across wide swathes of the world, and all of them, with the exception of malaria, are classified as &amp;quot;neglected&amp;quot;. In addition, mPPases also occur in Bacteroides vulgatus, which is the most common cause of brain abscesses. B. vulgatus is both very hard to treat and is a reservoir for antibiotic resistance because Bacteroides spp are extremely drug-resistant. 

Our plan is to use a multidisciplinary experimental approach (i.e. membrane protein x-ray crystallography, single-molecule fluorescence microscopy, fast electrometry and state-of-the-art fast photochemical oxidation/mass spectrometry (FPOP/MS) tied together with steered molecular dynamics to determine the full range of motions with the potential to exploit transient states as drug targets.

We will solve structures of different classes of mPPases, especially ones from the protozoan parasites and Bacteroides, to understand differences in pumping and as the basis for future small molecule inhibitor design. We will use single molecule spectroscopy to identify motions in the helices leading to gate opening and thus ion pumping. The fast electrometry will determine the kinetics of charge movement across the membrane versus the kinetics of hydrolysis, and FPOP/MS will identify changes in the exposed surface of TmPPase with microsecond time resolution.

All of this work will then be integrated within a molecular dynamics model to explain how the enzyme functions, including computational predictions of the structures of kinetic states that are inaccessible experimentally. Understanding the structure of the &amp;quot;gate open&amp;quot; state will enable the next stage: identifying molecules that keep the pumps always-open. Such molecules would be highly-specific drug candidates. They would affect only a few classes of pathogens, but would be completely lethal for them.</gtr:abstractText><gtr:technicalSummary>Integral membrane pyrophosphatases (mPPases) are evolutionarily conserved novel &amp;quot;primary&amp;quot; ion pumps, interconverting the free energy in the phosphoanhydride bond of pyrophosphate into a sodium and/or proton motive force. They occur in plants, apicomplexan parasites and in (archae)bacteria but not in multicellular animals, and they appear to be essential under conditions of low-energy stress: knockout mutations render apicomplexan parasites such as Toxoplasma and Trypanosoma non-infectious, for instance. Their coupling mechanism is essentially unknown. Our vision is to use structural, single molecule and functional studies to identify the precise mechanism of action in mPPase as the necessary first step for developing specific inhibitors. This work will have important benefits for animal health, food security, and human disease since e.g. protozoan parasites like Trypanosoma spp (Nagana, sleeping sickness), Toxoplasma gondii (infecting up to 90% of pigs), not to mention Plasmodium falciparum (malaria) cause serious diseases

Our overarching vision is to understand the complete atomic mechanism of integral membrane ion-pumping pyrophosphatases as the necessary first step for developing drug-like molecules. Our main objectives are thus:
1. Solving structures of integral membrane proton-pumping pyrophosphatases from disease causing organisms (Bacteroides and apicomplexa)

2. Complementing the structural information through fast kinetics and single molecule work to gain insight into the transient &amp;quot;gate-open&amp;quot; species that leads to pumping. Molecular dynamics simulations that give testable information about &amp;quot;gate-open&amp;quot; and other transient states and provide hypotheses about the basis of ion-pumping specificity (proton versus sodium versus both).

The main techniques we will use are x-ray crystallography, single molecule fluorescence microscopy, electrometry, fast photochemical oxidation/mass spectrometry and steered molecular dynamics.</gtr:technicalSummary><gtr:potentialImpactText>The immediate, short-term beneficiaries of this fundamental research will be other academics, as outlined in the academic beneficiaries section. However, in the medium to long term, the non-academic beneficiaries of this work fall into three main classes:
1) The wider public, through improved global health and food security
2) The commercial private sector, through improved options for novel product development and commercial revenue
3) Charities within the non-public sector

This proposal focuses on structural and functional understanding of a novel membrane protein, the integral membrane pyrophosphatase (mPPase). mPPases do not occur in mammals nor in most bacteria, but are essential under conditions of low-energy stress in both protozoan parasites and the anaerobic opportunistic pathogen Bacteroides. This project will lay the groundwork for future development of molecules that target these pathogens highly specifically. Protozoan parasites, such as P. falciparum (malaria: 207M cases in 2012) and Toxoplasma gondii (infection rates as high as 90% in pigs), are major contributors to both animal and human morbidity and mortality. Many are on the WHO list of neglected tropical diseases.

Global health and food security. Being able to target specific proteins that are unique to the pathogenic organisms will reduce the problem of drug resistance: only the &amp;quot;bad&amp;quot; species is targeted, so there is no selection pressure on other organisms to acquire and spread resistance. 

Industrial involvement. SMEs and big pharmaceutical companies will benefit from this research. Researchers at Leeds work with companies, including MedImmune and GlaxoSmithKline; and AG has had grant funding from Merck and collaborates with Novartis and the California SME ActivX. It is widely accepted that infectious diseases are no longer a thing of the past. This work will present new targets for the companies for use both in animal and human health, and will be relevant not only to protozoan diseases but also in treating Bacteroides brain abscesses, with an associated mortality of 20%. The timeframe for development is 5-15 years but this work provides the fundamental research on which it will be based.

Academic stakeholders. We will communicate with academic stakeholders by giving high-visibility seminars at major conferences and universities, and by publishing our research in the very best journals. 

Developing highly skilled people. A major transferrable benefit of all academic research is the people trained during the project. The PDRA on the project will acquire multiple specialist scientific skills (membrane protein crystallography, TIRF, FPOP/MS) to use in research-based biotechnological industry and academia. In addition the University of Leeds has an extensive career development program that will provide transferrable skills. These trained people, as they move to other institutions in academia, in government and in industry, will affect the larger society positively.

Public health stakeholders. We have a strong track record in disseminating their research and contributing to the public understanding of science in England and in Europe. New approaches to these diseases is important for national and international stakeholders, ranging from the Department of Overseas Development to international health charities and WHO. 

Reaching the general public. Work with potential to lead to superior outcomes will be disseminated widely (TV, radio, YouTube, press releases). Atomistic MD simulations are particularly useful for science communication, and will be used to explain findings to a general audience. Our focus is also on enthusing and training the next generation of scientists. We will also continue to engage with students in secondary education, by inspiring visiting UCAS students, by annual Discovery Zone workshops to enthuse school children to study science and by being STEM (Science Technology Engineering and Maths) ambassadors.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2015-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>420691</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Chemistry Leeds</gtr:department><gtr:description>Collaboration on integral membrane Pyrophosphates</gtr:description><gtr:id>DE674134-1F81-4A3C-B3B7-3AE263376369</gtr:id><gtr:impact>Goldman, A., af Genn&amp;auml;s, G. B., Xhaard, H., Meri, S. &amp;amp; Yli-Kauhaluoma, J. Pyrofosfaatti l&amp;auml;&amp;auml;ketieteess&amp;auml;. Duodecim in press, (2016).

Multidisciplinary collaboration
Crystallography, protein chemistry, biophysics, enzymology, drug design, protein modelling</gtr:impact><gtr:partnerContribution>Provide novel inhibitor design, intellectual input into new drugs, testing of new molecules in Plasmodium falciparum and animal models</gtr:partnerContribution><gtr:piContribution>Provide protein, intellectual input into possible modifications, binding studies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Helsinki</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:department>Division of Pharmaceutical Chemistry and Technology</gtr:department><gtr:description>Collaboration on integral membrane Pyrophosphates</gtr:description><gtr:id>A6AC3136-D4A4-4AD4-AEDF-EFCC3D3F0C63</gtr:id><gtr:impact>Goldman, A., af Genn&amp;auml;s, G. B., Xhaard, H., Meri, S. &amp;amp; Yli-Kauhaluoma, J. Pyrofosfaatti l&amp;auml;&amp;auml;ketieteess&amp;auml;. Duodecim in press, (2016).

Multidisciplinary collaboration
Crystallography, protein chemistry, biophysics, enzymology, drug design, protein modelling</gtr:impact><gtr:partnerContribution>Provide novel inhibitor design, intellectual input into new drugs, testing of new molecules in Plasmodium falciparum and animal models</gtr:partnerContribution><gtr:piContribution>Provide protein, intellectual input into possible modifications, binding studies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>DiscoveryZone</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FFB2FC1E-AD74-4F5D-8CEB-348A2C4F933E</gtr:id><gtr:impact>300 keystage 2 and 3 pupils attend and are engaged in hands-on scientific activities from over 30 different stations.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.fbs.leeds.ac.uk/outreach/schools/lfos.php</gtr:url><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Student visits for the Baldwin memorial symposium</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>48760379-4916-4998-BF35-73654ECA278E</gtr:id><gtr:impact>127 keystone 4 pupils from local schools attended a public lecture by the Nobelist Professor Sir John Walker, FRS, and also were involved in a visit to the laboratories. They had an introduction to scientific techniques, sparking interest in biological research areas.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.fbs.leeds.ac.uk/baldwin/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>183000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Marie Curie postdoctoral fellowship</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Marie Curie Actions</gtr:fundingOrg><gtr:id>D008B237-AB23-41CC-9C4A-620423275EB7</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>546580</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Marie Curie Innovative Training Network</gtr:description><gtr:end>2021-03-02</gtr:end><gtr:fundingOrg>European Union</gtr:fundingOrg><gtr:id>B08E0989-54F7-4C86-BD2D-78069F725E9B</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>83000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Global Challenges Research Fund</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:fundingRef>CH160038</gtr:fundingRef><gtr:id>BC54B5DC-FAC5-408F-A292-231C6807986B</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We work on integral membrane pyrophosphatases, which occur in bacteria, archaebacteria, plants, and protozoan parasites that cause disease like malaria and leishmania - but that do not occur in humans or other animals. They are thus potential drug targets. The enzymes create charge gradients that enable the cells to function. We have discovered how the enzyme works at the molecular level, and we published that in Nature Communications in 2016. This work describes two different enzymes, one from plants and one from an archaebacterium. In addition, we have begun drug design and screening studies, and have been able to find about 5 compounds that appear to inhibit the enzyme at micromolar level in tests. One of these compounds also kills the malaria parasites in the red blood cell assay, so it is actually a potential new drug that we now need to optimise. It has the great advantage over many other starting compounds in that there is no reason to believe that it will bind to human proteins, because there are no similar proteins to the integral membrane pyrophosphatase in the human body.</gtr:description><gtr:exploitationPathways>Other groups can use the work to develop pyrophosphate-based batteries, which could be solar-powered. In addition, other groups both here and in Finland are exploiting the structures to develop novel compounds that may become a novel class of antimalarial drugs.</gtr:exploitationPathways><gtr:id>B15DFA69-7F87-4D08-868D-43D44F18377A</gtr:id><gtr:sectors><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed a PAGE-based version of the classical colourimetric assay for pyrphosphatases (PPases). The assay in solution uses a molybdate-based reaction to form a colour compound that can be detected at 700 nm. We were able to determine that it is possible to run the same assay in PAGE and detect using conventional gel imaging, providing a way of determining amounts of active protein before final purification.</gtr:description><gtr:id>3C96C20E-DA92-4B58-8FF1-06D7CCE19950</gtr:id><gtr:impact>We have been using it to optimise membrane protein purification of various integral membrane pyrophosphatases. It has been used in new papers from the laboratory, and one is in preparation describing the method.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Rapid method for determining pyrophosphatase activity</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7222B9BA-0AA4-4B34-AA80-1AF9D35B0D02"><gtr:id>7222B9BA-0AA4-4B34-AA80-1AF9D35B0D02</gtr:id><gtr:title>Integral membrane pyrophosphatases: a novel drug target for human pathogens?</gtr:title><gtr:parentPublicationTitle>AIMS Biophysics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8dd4f9aa2ec74658b351783b0de1d28c"><gtr:id>8dd4f9aa2ec74658b351783b0de1d28c</gtr:id><gtr:otherNames>Goldman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6B36D28F-9AA3-402E-9782-AB32EE0FF18B"><gtr:id>6B36D28F-9AA3-402E-9782-AB32EE0FF18B</gtr:id><gtr:title>Baculovirus-mediated expression of GPCRs in insect cells.</gtr:title><gtr:parentPublicationTitle>Methods in enzymology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/625079b00268695eb9421b5ed463a838"><gtr:id>625079b00268695eb9421b5ed463a838</gtr:id><gtr:otherNames>Saarenp?? T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:isbn>9780128015216</gtr:isbn><gtr:issn>0076-6879</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/92E4921C-C994-41D2-A684-CC77F77257AA"><gtr:id>92E4921C-C994-41D2-A684-CC77F77257AA</gtr:id><gtr:title>A method for detergent-free isolation of membrane proteins in their local lipid environment.</gtr:title><gtr:parentPublicationTitle>Nature protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e04bb8dff19698767ea5b2f24eab8811"><gtr:id>e04bb8dff19698767ea5b2f24eab8811</gtr:id><gtr:otherNames>Lee SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1750-2799</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/79E14A13-D202-4C69-93C2-32D99E1A64FA"><gtr:id>79E14A13-D202-4C69-93C2-32D99E1A64FA</gtr:id><gtr:title>Transport mechanism of a glutamate transporter homologue GltPh.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/91ebed6dd9d1d246897de1d85918d8fc"><gtr:id>91ebed6dd9d1d246897de1d85918d8fc</gtr:id><gtr:otherNames>Ji Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/585F593B-6A03-4B99-A8C2-D2D6B111F04C"><gtr:id>585F593B-6A03-4B99-A8C2-D2D6B111F04C</gtr:id><gtr:title>Membrane pyrophosphatases from Thermotoga maritima and Vigna radiata suggest a conserved coupling mechanism.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/db1dc1ff17c363710aae3f2795c858d0"><gtr:id>db1dc1ff17c363710aae3f2795c858d0</gtr:id><gtr:otherNames>Li KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C6E10795-2294-42A4-BB17-5D57E3F493E1"><gtr:id>C6E10795-2294-42A4-BB17-5D57E3F493E1</gtr:id><gtr:title>A Novel and Fast Purification Method for Nucleoside Transporters.</gtr:title><gtr:parentPublicationTitle>Frontiers in molecular biosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7045baff94647ff4a636afc145a388a6"><gtr:id>7045baff94647ff4a636afc145a388a6</gtr:id><gtr:otherNames>Hao Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2296-889X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/696A26C1-D8EE-46F3-BF13-51999B019C75"><gtr:id>696A26C1-D8EE-46F3-BF13-51999B019C75</gtr:id><gtr:title>Artificial membranes for membrane protein purification, functionality and structure studies.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c7761f29ec77f91b6a8bffd78d98a081"><gtr:id>c7761f29ec77f91b6a8bffd78d98a081</gtr:id><gtr:otherNames>Parmar MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/12351F52-D97A-42A0-9566-727C9077E53A"><gtr:id>12351F52-D97A-42A0-9566-727C9077E53A</gtr:id><gtr:title>Insights into the mechanism of membrane pyrophosphatases by combining experiment and computer simulation.</gtr:title><gtr:parentPublicationTitle>Structural dynamics (Melville, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ceea6e255f5361f7f7375730295637d3"><gtr:id>ceea6e255f5361f7f7375730295637d3</gtr:id><gtr:otherNames>Shah NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2329-7778</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/M021610/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>F442B6BE-8B89-4C01-8D3B-E8A4D320B672</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biomolecules &amp; biochemistry</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>9CD2DA3B-F052-4076-95ED-10F46E76C382</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Optics, photonics &amp; lasers</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>D22AE401-1C35-4706-A19C-10861ABC82CD</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biological membranes</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>02FE9751-1497-4DFD-B349-D4A9C96538E1</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biophysics</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>B971A4E6-FF4B-45BC-96D6-1E289961490D</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Catalysis &amp; enzymology</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>F14C04A0-571D-4298-AEAC-AEC5A0A9DB7D</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Structural Biology</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>